Dengue Fever – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Dengue Fever Market Outlook
Thelansis’s “Dengue Fever Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Dengue Fever treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Dengue Fever Overview
Dengue
virus infection is the most widespread arthropod-borne viral illness in humans.
It is primarily transmitted by Aedes mosquitoes, including A. aegypti and A.
albopictus, which become infected by biting a person with the virus in their
bloodstream. Dengue fever typically becomes symptomatic after an incubation
period of 4-10 days, with symptoms lasting 2-7 days. Many patients with dengue
may not exhibit any symptoms, while others may experience chills, rash,
erythematous mottling of the skin, and facial flushing for 2-3 days. Severe
dengue fever occurs in less than 5% of cases, with most fatalities occurring in
children and adolescents. Severe dengue, also known as Dengue hemorrhagic fever
or Dengue shock syndrome, is characterized by increased vascular permeability,
leading to hypovolemic shock and death. The Dengue virus has four serotypes
(DEN-1, DEN-2, DEN-3, and DEN-4). The disease can progress to severe dengue
fever, leading to damaged blood vessels and fluid leakage, decreased platelet
count causing severe bleeding, sudden blood pressure drops, and systemic
failure that may culminate in death.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment